TheraRadar
← Back
Data updated: May 24, 2026

REGCON HOLDINGS

Generics

REGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

1999
Since
42
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 35%
6 drugs
Neurology 29%
5 drugs
Ophthalmology 12%
2 drugs
Gastroenterology 12%
2 drugs
Oncology 12%
2 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling